By Fineline Cube 
Suzhou-based MEI Medical Technologies Co., Ltd., a medical device manufacturer specializing in peripheral vascular intervention, tumor intervention, and hemodialysis pathways maintenance, announced that it has raised RMB 100 million (USD 14 million) in a new financing round. The investors included Suzhou Capital Group, TTGG Ventures, Guanghua Wutong Equity Investment Fund, and Medpark. This marks the second time this year that MEI Med has secured RMB 100 million in funding, following a similar round in January backed by HongShan, EFung Capital, and others.
Technological Breakthrough
Founded in 2021 in Suzhou High-Tech District, MEI Medical has achieved a significant milestone by mastering the mass production of medical implant-grade expanded polytetrafluoroethylene (ePTFE) material. This breakthrough addresses a long-standing technical bottleneck in the medical field. The company has successfully completed National Medical Products Administration (NMPA) master file registrations for its ePTFE tubing and membrane products.
Product Applications
MEI Medical’s ePTFE material has broad application potential in the medical device industry. The company has customized and upgraded ePTFE solutions for multiple medical device manufacturers across various specialized fields, leveraging its expertise to enhance product performance and reliability.-Fineline Info & Tech